Antiendotoxin strategies for the prevention and treatment of septic shock. New approaches and future directions.

Abstract:

:Therapy for Gram-negative sepsis remains unsatisfactory despite a concerted effort to develop new treatments for this common, life-threatening syndrome. Current research continues on several fronts to improve the treatment options available to clinicians in the management of these critically ill patients. Recently, a greater understanding of the complex molecular basis of endotoxin-mediated pathophysiological effects in humans has generated a number of novel therapeutic agents for sepsis. Several of these treatment strategies have already entered clinical trials and it is hoped that some of these therapies will become widely available in the near future. In this review, the current status of the most promising new antiendotoxin agents is summarised, and the major obstacles to the successful clinical development of these therapies are described. New antiendotoxin therapies include those which interrupt the synthesis of endotoxin, bind and neutralise its activity, prevent endotoxin interactions with host effector cells and interfere with endotoxin-mediated signal transduction pathways. Potential therapeutic strategies involving these agents consist of endotoxin analogues, antibodies, subunit vaccines, binding columns, recombinant human proteins and small molecule inhibitors of endotoxin synthesis and intracellular signalling. The pitfalls of previous antiendotoxin clinical investigations and the perils of future clinical trial designs are discussed in the context of unmet needs and realistic expectations for success. While considerable progress has been made, effective and new treatments for Gram-negative bacterial sepsis continues to elude us at the present time. This has been to the detriment of patients, investigators and pharmaceutical companies alike. It will require focused efforts by basic scientists, continued support by industry and enlightened study designs by clinical investigators to successfully develop antiendotoxin in therapies for use in septic patients in the future.

journal_name

Drugs

journal_title

Drugs

authors

Opal SM,Yu RL Jr

doi

10.2165/00003495-199855040-00002

subject

Has Abstract

pub_date

1998-04-01 00:00:00

pages

497-508

issue

4

eissn

0012-6667

issn

1179-1950

journal_volume

55

pub_type

杂志文章,评审

相关文献

DRUGS文献大全
  • Treating ocular hypertension to reduce glaucoma risk: when to treat?

    abstract::When to treat the patient who presents with ocular hypertension has been a question that has 'stumped' the ophthalmic community for decades. Population-based studies and intervention trials have provided the basis for understanding why we consider treating such patients. Although the EGPS (European Glaucoma Prevention...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200666080-00001

    authors: Higginbotham EJ

    更新日期:2006-01-01 00:00:00

  • Remission, a therapeutic goal in inflammatory arthropathies? Clinical data from adalimumab studies.

    abstract::In recent years, there have been major advances in the management of rheumatoid arthritis (RA), leading to the development of tumour necrosis factor (TNF) antagonists. With these agents, it is possible to arrest joint damage and, by treating early in the disease course, to prevent joint damage. It is also now thought ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200666140-00001

    authors: Montecucco C

    更新日期:2006-01-01 00:00:00

  • Amorolfine. A review of its pharmacological properties and therapeutic potential in the treatment of onychomycosis and other superficial fungal infections.

    abstract::Amorolfine is a structurally unique, topically active antifungal agent, which possesses both fungistatic and fungicidal activity in vitro. Its spectrum of in vitro activity includes dermatophyte, dimorphic, some dematiaceous and filamentous fungi, and some yeasts. In clinical trials, application of amorolfine 5% nail ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199549010-00008

    authors: Haria M,Bryson HM

    更新日期:1995-01-01 00:00:00

  • The polyol pathway. A historical review.

    abstract::Polyhydric alcohols (polyols) are widely distributed in nature, and the enzymes of the polyol pathway (aldose reductase and sorbitol dehydrogenase) are present in many mammalian tissues. The function of this pathway remains a mystery. A primary role for the pathway in the pathogenesis of 'sugar cataract' was provided ...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198600322-00003

    authors: Clements RS Jr

    更新日期:1986-01-01 00:00:00

  • Remifentanil: a review of its use during the induction and maintenance of general anaesthesia.

    abstract::Remifentanil (Ultiva), a fentanyl derivative, is an ultra-short acting, nonspecific esterase-metabolised, selective mu-opioid receptor agonist, with a pharmacodynamic profile typical of opioid analgesic agents. Notably, the esterase linkage in remifentanil results in a unique and favourable pharmacokinetic profile for...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200565130-00007

    authors: Scott LJ,Perry CM

    更新日期:2005-01-01 00:00:00

  • Cisatracurium besilate. A review of its pharmacology and clinical potential in anaesthetic practice.

    abstract::Cisatracurium besilate (besylate) is a nondepolarising neuromuscular blocking agent with an intermediate duration of action. It is the R-cis, R'-cis isomer of atracurium besilate and is approximately 3-fold more potent than the mixture of isomers that constitute the parent drug. The ED95 for cisatracurium besilate (do...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199753050-00012

    authors: Bryson HM,Faulds D

    更新日期:1997-05-01 00:00:00

  • Landiolol: A Review in Tachyarrhythmias.

    abstract::Intravenous landiolol [Rapibloc® (EU)], an ultra short-acting highly cardioselective β1-blocker, is approved in the EU for the rapid short-term control of tachyarrhythmias in the perioperative and intensive care settings. It has long been used in Japan to treat perioperative tachyarrhythmias. The efficacy of landiolol...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-018-0883-9

    authors: Syed YY

    更新日期:2018-03-01 00:00:00

  • Effect of nedocromil sodium on the bronchoconstrictor effect of neurokinin A in asthmatics.

    abstract::In a double-blind, crossover study we have investigated the effect of nedocromil sodium on neurokinin A (NKA)-induced bronchoconstriction in asthmatics. 12 patients with mild asthma inhaled either nedocromil sodium 4mg or placebo, on 2 separate days, as 2 puffs from a metered-dose aerosol 30 minutes before challenge w...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章

    doi:10.2165/00003495-198900371-00019

    authors: Joos GF,Pauwels RA,Van der Straeten ME

    更新日期:1989-01-01 00:00:00

  • Zimelidine: a review of its pharmacological properties and therapeutic efficacy in depressive illness.

    abstract::Zimelidine is a new antidepressant, which is structurally unrelated to the tricyclic and tetracyclic antidepressants. The pharmacological profile of zimelidine is different to that of other antidepressants in that it appears to owe the major part of its activity to the inhibition of serotonin uptake within the central...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198224030-00001

    authors: Heel RC,Morley PA,Brogden RN,Carmine AA,Speight TM,Avery GS

    更新日期:1982-09-01 00:00:00

  • Drug stimulated biotransformation of hormonal steroid contraceptives: clinical implications.

    abstract::On the basis of well documented biochemical and pharmacological data about the influence of drug mediated enzyme induction on the biotransformation of natural and synthetic sex steroids, practical consequences for hormonal steroid contraception are described and discussed. Clinical reports dealing with this problem ar...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-197612060-00003

    authors: Hempel E,Klinger W

    更新日期:1976-12-01 00:00:00

  • Fluticasone furoate: intranasal use in allergic rhinitis.

    abstract::Fluticasone furoate nasal spray is a new topical intranasal corticosteroid with enhanced affinity for the glucocorticoid receptor and low systemic exposure, which was recently approved in the US for the treatment of seasonal or perennial allergic rhinitis in adults and in children aged >or=2 years. Fluticasone furoate...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200767130-00010

    authors: McCormack PL,Scott LJ

    更新日期:2007-01-01 00:00:00

  • Defining the role of trimetazidine in the treatment of cardiovascular disorders: some insights on its role in heart failure and peripheral artery disease.

    abstract::Trimetazidine is a cytoprotective drug whose cardiovascular effectiveness, especially in patients with stable ischemic heart disease, has been the source of much controversy in recent years; some have gone so far as to treat the medication as a 'placebo drug' whose new side effects, such as Parkinsonian symptoms, outw...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-014-0233-5

    authors: Chrusciel P,Rysz J,Banach M

    更新日期:2014-06-01 00:00:00

  • The coming era of quadrivalent human influenza vaccines: who will benefit?

    abstract::Influenza vaccines form the mainstay of public health and personal protection against infection with seasonal influenza viruses. These vaccines are designed to protect people against infection with the currently circulating influenza viruses. Since the late 1970s, this has required the use of a trivalent vaccine consi...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/11641110-000000000-00000

    authors: Barr IG,Jelley LL

    更新日期:2012-12-03 00:00:00

  • Lemborexant: First Approval.

    abstract::Lemborexant (DAYVIGO™) is an orally administered, dual orexin receptor (OXR) antagonist that exhibits reversible competitive antagonism at OXR1 and OXR2 (> affinity at OXR2) that was discovered and developed by Eisai Inc. for the treatment of adult patients with insomnia. In December 2019, lemborexant received its fir...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01276-1

    authors: Scott LJ

    更新日期:2020-03-01 00:00:00

  • Darunavir: a review of its use in the management of HIV infection in adults.

    abstract:UNLABELLED:Darunavir is an oral nonpeptidic HIV-1 protease inhibitor (PI) that is used, together with a low boosting dose of ritonavir, as part of an antiretroviral therapy (ART) regimen in treatment-experienced and -naive patients with HIV-1 infection. Compared with early-generation PIs, boosted darunavir has a high g...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200969040-00007

    authors: McKeage K,Perry CM,Keam SJ

    更新日期:2009-01-01 00:00:00

  • Cefadroxil in the treatment of susceptible infections in infants and children.

    abstract::The efficacy and safety of cefadroxil in the treatment of paediatric patients with a wide variety of infections were evaluated in a multicentre clinical trial. This study included 395 infants and children with Group A streptococcal pharyngitis, sinusitis, otitis media, bronchitis, pneumonia or bronchopneumonia, urinar...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198600323-00005

    authors: Puhakka H,Virolainen E

    更新日期:1986-01-01 00:00:00

  • A guide to the treatment of lower respiratory tract infections.

    abstract::Acute bronchitis is usually a viral infection which, unless there is a special disposition, does not require antibiotic therapy. For the initial oral chemotherapy of bacterial infections of the lower respiratory tract (chronic bronchitis, pneumonia) the effective and well tolerated cephalosporins, macrolides and amoxi...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199550010-00006

    authors: Vogel F

    更新日期:1995-07-01 00:00:00

  • Current pharmacological approaches to the therapy of varicella zoster virus infections: a guide to treatment.

    abstract::Varicella zoster virus (VZV), a member of the herpesvirus family, is responsible for both primary (varicella, chickenpox) as well as reactivation (zoster, shingles) infections. In immunocompetent patients, the course of varicella is generally benign. For varicella zoster, post-herpetic neuralgia is the most common com...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199957020-00005

    authors: Snoeck R,Andrei G,De Clercq E

    更新日期:1999-02-01 00:00:00

  • Semaglutide: First Global Approval.

    abstract::Novo Nordisk has developed a subcutaneous formulation of semaglutide (Ozempic®), a modified human glucagon-like peptide-1 (GLP-1) analogue, for the treatment of type 2 diabetes mellitus. It has been developed using Novo Nordisk's proprietary protein-acylation technology, and is administered using an injection device. ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-018-0871-0

    authors: Dhillon S

    更新日期:2018-02-01 00:00:00

  • Potential of aromatase inhibitors for ovulation and superovulation induction in infertile women.

    abstract::For almost half a century, the first-line treatment for ovulation induction in cases of anovulation, unexplained infertility, or mild male factor has been clomifene (clomiphene citrate). Clomifene is an effective and safely used oral agent, but is known to have relatively common antiestrogenic endometrial and cervical...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200666170-00001

    authors: Mitwally MF,Casper RF

    更新日期:2006-01-01 00:00:00

  • Parenteral cephalosporin therapy in ambulatory care: advantages and disadvantages.

    abstract::Outpatient parenteral antibiotic therapy (OPAT) programmes are effective, well tolerated and economically advantageous in carefully selected patient populations. Inclusion criteria for patient selection for OPAT include good clinical appearance and uncomplicated infection. By virtue of their favourable microbiological...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200059003-00003

    authors: Esposito S

    更新日期:2000-01-01 00:00:00

  • Correction to: Isatuximab: First Approval.

    abstract::In the table 'Key clinical trials of isatuximab (Sanofi)', in the left-hand column. ...

    journal_title:Drugs

    pub_type: 杂志文章,已发布勘误

    doi:10.1007/s40265-020-01325-9

    authors: Dhillon S

    更新日期:2020-06-01 00:00:00

  • Ciclesonide nasal spray: in allergic rhinitis.

    abstract::Ciclesonide nasal spray delivers the corticosteroid ciclesonide as a hypotonic spray via a metered-dose manual pump. Systemic exposure to ciclesonide and its active metabolite desisobutyryl-ciclesonide is low after intranasal administration. High protein binding (approximately 99%) and rapid first-pass clearance furth...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200868060-00009

    authors: Dhillon S,Wagstaff AJ

    更新日期:2008-01-01 00:00:00

  • Updated national and international hypertension guidelines: a review of current recommendations.

    abstract::Despite the availability of effective pharmacological treatments to aid the control of blood pressure, the global rate of uncontrolled blood pressure remains high. As such, further measures are required to improve blood pressure control. Recently, several national and international guidelines for the management of hyp...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-014-0306-5

    authors: Kjeldsen S,Feldman RD,Lisheng L,Mourad JJ,Chiang CE,Zhang W,Wu Z,Li W,Williams B

    更新日期:2014-11-01 00:00:00

  • Practical aspects of the use of amiodarone.

    abstract::Amiodarone is a class III antiarrhythmic drug with sympatholytic properties, which prolongs the refractory period of all cardiac tissues, depresses sinus node automaticity and atrioventricular nodal conduction. It is active on all cardiac arrhythmias, its use being limited by the risk of side effects, mainly extracard...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199100412-00009

    authors: Puech P

    更新日期:1991-01-01 00:00:00

  • Somatropin (Zorbtive): in short bowel syndrome.

    abstract::A somatropin preparation (Zorbtive) produced by recombinant DNA technology has been evaluated in patients with short bowel syndrome. Somatropin is thought to enhance intestinal adaptation in this condition through direct or indirect effects on the intestine. In a randomised, double-blind study in patients with short b...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200464120-00008

    authors: Keating GM,Wellington K

    更新日期:2004-01-01 00:00:00

  • HMG-CoA reductase inhibitors in chronic heart failure: potential mechanisms of benefit and risk.

    abstract::HMG-CoA reductase inhibitors (statins) have been shown to reduce mortality and cardiovascular morbidity in patients with hyperlipidaemia and those with coronary artery disease. However, evidence for statin treatment in patients with chronic heart failure (CHF) remains a subject of debate. Patients with heart failure w...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200666020-00002

    authors: Laufs U,Custodis F,Böhm M

    更新日期:2006-01-01 00:00:00

  • [Atenolol/nifedipine combination: efficacy and tolerability of low dose synergistic bitherapy in the treatment of arterial hypertension].

    abstract::During recent decades, undeniable progress has been made with regard to the management of arterial hypertension. Larger numbers of patients are aware they have hypertension, receive treatment and benefit from this therapy. Furthermore, significant reductions have been observed in morbidity and mortality resulting from...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199856002-00004

    authors: Krivitzky A,Nguyen G,Gaudouen Y,Legrand M,Cohen R

    更新日期:1998-01-01 00:00:00

  • An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson's disease and restless legs syndrome.

    abstract::This narrative review reports on the pharmacological and pharmacokinetic properties of rotigotine, a non-ergolinic D₃/D₂/D₁ dopamine receptor agonist approved for the treatment of early- and advanced-stage Parkinson's disease (PD) and moderate to severe restless legs syndrome (RLS). Rotigotine is formulated as a trans...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-015-0377-y

    authors: Elshoff JP,Cawello W,Andreas JO,Mathy FX,Braun M

    更新日期:2015-04-01 00:00:00

  • Community-associated meticillin-resistant Staphylococcus aureus infections: epidemiology, recognition and management.

    abstract::Meticillin-resistant Staphylococcus aureus (MRSA) is an important cause of infection, particularly in hospitalized patients and those with significant healthcare exposure. In recent years, epidemic community-associated MRSA (CA-MRSA) infections occurring in patients without healthcare risk factors have become more fre...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200969060-00004

    authors: Patel M

    更新日期:2009-01-01 00:00:00